Anika Therapeutics (ANIK)

Anika Therapeutics Stock Analysis & Ratings

ANIK Stock Chart & Stats

Day’s Range$20.97 - $22.31
52-Week Range$19.95 - $48.37
Previous Close$21.89
Average Volume (3M)88.63K
Market Cap$307.60M
P/E Ratio-183.3
Next EarningsJul 27, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score7
EPS (TTM)-0.12



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Anika Therapeutics’s price range in the past 12 months?
Anika Therapeutics lowest stock price was $19.95 and its highest was $48.37 in the past 12 months.
    What is Anika Therapeutics’s market cap?
    Anika Therapeutics’s market cap is $307.60M.
      What is Anika Therapeutics’s price target?
      The average price target for Anika Therapeutics is $35.00. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $35.00 ,the lowest forecast is $35.00. The average price target represents 65.48% Increase from the current price of $21.15.
        What do analysts say about Anika Therapeutics?
        Anika Therapeutics’s analyst rating consensus is a ‘Hold. This is based on the ratings of 2 Wall Streets Analysts.
          When is Anika Therapeutics’s upcoming earnings report date?
          Anika Therapeutics’s upcoming earnings report date is Jul 27, 2022 which is in 68 days.
            How were Anika Therapeutics’s earnings last quarter?
            Anika Therapeutics released its earnings results on May 05, 2022. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.333 by $0.133.
              Is Anika Therapeutics overvalued?
              According to Wall Street analysts Anika Therapeutics’s price is currently Undervalued.
                Does Anika Therapeutics pay dividends?
                Anika Therapeutics does not currently pay dividends.
                What is Anika Therapeutics’s EPS estimate?
                Anika Therapeutics’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Anika Therapeutics have?
                Anika Therapeutics has 14,540,000 shares outstanding.
                  What happened to Anika Therapeutics’s price movement after its last earnings report?
                  Anika Therapeutics reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.333. Following the earnings report the stock price went up 2.237%.
                    Which hedge fund is a major shareholder of Anika Therapeutics?
                    Among the largest hedge funds holding Anika Therapeutics’s share is Fisher Asset Management LLC. It holds Anika Therapeutics’s shares valued at 3M.


                      Anika Therapeutics Stock Analysis

                      Smart Score
                      Price Target
                      ▲(65.48% Upside)
                      The Anika Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Anika Therapeutics

                      Anika Therapeutics, Inc. is an orthopedic and regenerative medicines company, which develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical, ophthalmic and veterinary. The company was founded in 1992 and is headquartered in Bedford, MA.

                      Similar Stocks
                      Price & Change
                      Johnson & Johnson
                      Zimmer Biomet Holdings
                      KalVista Pharmaceuticals

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis